Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPH insulin · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Insulin detemir | EXPERIMENTAL | Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn |
| Neutral Protamine Hagedorn (NPH) insulin | ACTIVE_COMPARATOR | Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn |
| NPH insulin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| insulin detemir | DRUG | Treat-to-target, dose titration, s.c. (under the skin) injection |
| NPH insulin | DRUG | Treat-to-target, dose titration, s.c. (under the skin) injection |
| insulin aspart | DRUG | Treat-to-target, dose titration, s.c. (under the skin) injection |
Inclusion Criteria: * Type 1 diabetes treated with insulin for at least 12 months * Planning to become pregnant and have a screening HbA1c (glycosylated haemoglobin) lesser than or equal to 9.0%, or * Pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when joining the trial ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NPH insulin is an intermediate-acting insulin used for the treatment of diabetes mellitus, including type 1 diabetes. It is administered to help control blood glucose levels in patients who require insulin therapy.
NPH insulin is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO.
NPH insulin is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. Clinical trials are ongoing to evaluate its efficacy and safety.
NPH insulin has been studied in two Phase 3 clinical trials. One trial (NCT00474045) evaluated its efficacy and safety in pregnant women with type 1 diabetes, enrolling 470 participants. Another trial (NCT03220425) compared NPH insulin with insulin detemir in subjects with type 1 diabetes, enrolling 752 participants. Both trials have been completed.
No, NPH insulin is not the same as insulin detemir. They are different insulin formulations. In clinical trials, insulin detemir has been compared with NPH insulin to evaluate their relative efficacy and safety in managing type 1 diabetes.